[SHINSA]Information Regarding Explanations to Driver Mutations in the Development of Anti-cancer Drugs（Early Consideration）posted.
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- PMDA Japan
- Region
- Japan
- Scope
- Regulatory
- Published
- June 29, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on pmda.go.jp
Leave the platform to read the original full article on the publisher site.
Source: PMDA Japan
Scope: Regulatory
Related coverage
More related coverage
Drug label update: Loperamide Hydrochloride
Official structured record identifier: 52e6ecc5-5f3d-9989-e063-6294a90af2dc.
Drug label update: NYSTATIN
Official structured record identifier: 50737729-a4a4-e747-e063-6394a90adcc5.
Reports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2025
This report shows all TB cases diagnosed in the UK including those detected at post-mortem.